Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab + Teclistamab in relapsed/refractory multiple myeloma
NCT04586426Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Mar 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of talquetamab, teclistamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Dec 2020; status: active, not recruiting.
02
Drugs
talquetamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04586426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586426.